News

A breakthrough in the treatment of advanced liver cancer has emerged through a novel combination of NK cell therapy, DC vaccine, and Nivolumab. This combined immunotherapy showed remarkable success, leading to significant tumor reduction and improved liver function in just six weeks for a patient with late-stage hepatocellular carcinoma.

At the 29th Asia-Pacific Blood and Marrow Transplantation (APBMT) Annual Meeting, Dr. Lu Peihua delivered a keynote address on the success of CAR-T cell therapy in China. Her team’s real-world data from clinical practice received international acclaim, showcasing their contributions to the treatment of blood malignancies.

In a pioneering clinical case, a 21-year-old patient successfully overcame the challenges of thalassemia through an advanced CRISPR-based gene therapy. This innovative approach marks a significant milestone in the treatment of severe blood disorders like sickle cell disease (SCD) and thalassemia.

At the upcoming ASH 2024 conference, the Lu Daopei Hospital medical team will present 13 groundbreaking research findings, highlighting advancements in hematology and the potential of CAR-T therapy, reaffirming their commitment to improving patient outcomes.

After battling lymphoma for three years, a 61-year-old woman achieved complete remission through innovative dual CAR-T therapy at BIOOCUS, showcasing the life-changing potential of advanced cancer treatments.

Recent advancements in CRISPR/Cas technology are reshaping the landscape of gene editing in biomedical research. This article explores its applications, highlighting the significant potential for treating genetic disorders, cancers, and infectious diseases.

A remarkable case at BIOOCUS showcases the transformative impact of CD7 CAR-T therapy in a 15-year-old boy with relapsed T-cell acute lymphoblastic leukemia (T-ALL), leading to complete remission and a successful second transplant.

Bioocus is excited to join the 8th Immuno-Gene and Cell Therapy Congress (IGC 2024)! We look forward to collaborating with global experts and exploring new business models that match cutting-edge gene and cell therapy technologies. Together, let’s shape the future of immunotherapy.

This news article highlights recent research on managing the toxicities of CAR-T cell therapy for B-cell lymphomas. The study emphasizes strategies to handle common side effects like cytokine release syndrome (CRS) and neurotoxicity (ICANS), ensuring safer use of this groundbreaking treatment.

The latest research highlights the efficacy and safety of CD7 CAR-T cell therapy in treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Conducted by BIOOCUS in collaboration with Lu Daopei Hospital, the study demonstrates promising outcomes for patients, offering a powerful alternative to conventional chemotherapy.

The study, published in the Journal of Clinical Oncology, demonstrates significant remission rates in patients who had exhausted traditional treatment options, marking a promising advancement in cancer therapy.

A recent study highlights the effectiveness of CD7 CAR-T therapy followed by a second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL), demonstrating significant potential in achieving minimal residual disease (MRD)-negative complete remission.